Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the publication of a ...
SOUTH SAN FRANCISCO, Calif. and BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on ...
Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS, and a key ...
Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS, and a key ...
Metabolism has always been a crucial pillar in cancer treatment, but clinical considerations have been limited to general diet and nutrition advice, minimizing the potential therapeutic impact of ...
Figure 1: Key signaling pathways and targeted factors in dysregulated BC. This figure illustrates the major signaling pathways and their intricate crosstalk in BC, focusing on the GPCR, RTKs, ...
BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month ...
Detailed price information for Bridgebio Oncology Therapeutics Inc (BBOT-Q) from The Globe and Mail including charting and trades.
Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American Association ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback